Managing Opioid Withdrawal Using COWS and Clonidine
For patients with opioid withdrawal, buprenorphine is superior to clonidine for symptom control and treatment retention, but when buprenorphine is unavailable or contraindicated, clonidine can be used as symptomatic treatment at 0.1 mg orally every hour as needed for non-hypotensive patients with moderate-to-severe withdrawal (COWS ≥8). 1
Assessment Algorithm Using COWS
Step 1: Confirm timing since last opioid use 1
- Short-acting opioids (heroin, morphine IR): >12 hours
- Extended-release formulations (OxyContin): >24 hours
- Methadone maintenance: >72 hours
Step 2: Calculate baseline COWS score 1
- COWS <8 (mild withdrawal): No buprenorphine indicated; reassess in 1-2 hours 1
- COWS ≥8 (moderate-to-severe withdrawal): Buprenorphine 4-8 mg sublingual is first-line; reassess after 30-60 minutes 1
Clonidine Dosing When Buprenorphine Unavailable
Critical caveat: Clonidine is less effective than buprenorphine or methadone for opioid withdrawal management and should only be used when opioid agonist therapy is not available. 1
Clonidine dosing protocol 1, 2:
- Initial dose: 0.1 mg orally twice daily (morning and bedtime) for hypertension dosing 2
- For acute withdrawal: 0.1 mg orally every hour as needed, monitoring blood pressure before each dose 1
- Maximum studied dose: 0.3 mg per administration in ED settings 3
- Contraindication: Do not administer if patient is hypotensive 1
Monitoring requirements 2:
- Check blood pressure before each dose
- Avoid in patients with baseline hypotension
- Watch for excessive sedation, bradycardia, and hypotension
Adjunctive Symptomatic Medications
Multimodal approach for symptom control 1:
- Nausea/vomiting: Promethazine or ondansetron 1
- Diarrhea: Loperamide 1
- Anxiety/muscle cramps: Benzodiazepines (reduce catecholamine release) 1
- Pain: Ibuprofen or acetaminophen 4
Evidence Hierarchy and Clinical Reasoning
Why buprenorphine is preferred: A Cochrane review found that patients receiving buprenorphine versus clonidine had less severe withdrawal symptoms, fewer adverse effects, and were more likely to complete treatment. 1 Meta-analysis ranked effectiveness as: buprenorphine > methadone > lofexidine > clonidine. 1
When clonidine may be necessary 1:
- No X-waiver available and cannot administer buprenorphine
- Patient refuses opioid agonist therapy
- Contraindications to buprenorphine (though rare)
- Bridge therapy while arranging opioid treatment program enrollment
Comparative effectiveness: In one ED trial, clonidine 0.3 mg required rescue medication in 63% of patients within 1 hour, compared to 27% with olanzapine, demonstrating clonidine's limited efficacy. 3
Critical Pitfalls to Avoid
Clonidine withdrawal risk 2:
- Abrupt discontinuation can cause rebound hypertension, agitation, headache, and elevated catecholamines
- When stopping clonidine, taper over 2-4 days 2
- Risk is higher with prolonged use at higher doses 2
COWS assessment timing 5:
- Patient-reported symptoms (SOWS) appear >10 hours before observer-rated symptoms (COWS) 5
- Most symptoms begin around 8 hours after last opioid dose 5
- COWS may underestimate early withdrawal severity 5
Precipitated withdrawal with buprenorphine 1, 6:
- Fentanyl bioaccumulates in adipose tissue with chronic use, increasing risk of precipitated withdrawal 1
- Ensure adequate time since last opioid use before buprenorphine administration 1
- If precipitated withdrawal occurs, magnesium sulfate 3g IV over 20 minutes followed by 10 mg/kg/h may provide relief 6
Transition to Definitive Treatment
All patients should be offered medication for opioid use disorder (MOUD) 4:
- Methadone and buprenorphine reduce overdose mortality (adjusted HR 0.52,95% CI 0.42-0.63) 4
- Only 25.1% of US patients with OUD received MOUD in 2022 4
- Provide naloxone kit and overdose education at discharge 1
- Arrange follow-up for MOUD initiation within 3-7 days 1
Regulatory considerations 1: